<DOC>
	<DOCNO>NCT01928823</DOCNO>
	<brief_summary>Since decade , D-Cycloserine ( DCS , drug class : Oxazolidinone ) proven effective antibiotic agent treatment tuberculosis . Furthermore take action central nervous system partial agonist NMDA receptor . Because glutamate mediate neuronal long-term potentiation long-term memory DCS augment effect emotional learning , occur exposure therapy anxiety disorder . In context use DCS addition exposure therapy part cognitive behavioral therapy ( CBT ) patient suffer agoraphobia without panic disorder . Thereby DCS applicated oral capsule 50mg , three consecutive therapy session .</brief_summary>
	<brief_title>Augmentation Psychotherapy With D-Cycloserine Agoraphobia</brief_title>
	<detailed_description>The present study multicenter study two participate institution : The `` Klinik für Psychiatrie und Psychotherapie , Charité - Universitätsmedizin Berlin '' `` ZPHU - Zentrum für Psychotherapie Institut für Psychologie , Humboldt-Universität zu Berlin '' . It randomize , placebo-controlled double blind study agoraphobic patient receive manualized cognitive behavioral therapy . The randomization blindness refers medication antibiotic call D-Cycloserine : One group receive D-Cycloserine exposure session group treat placebo . The aim find , whether D-Cycloserine augments psychotherapy outcome administer exposure . Altogether , 78 patient treat . Before therapy , patient receive clinical examination ensure contraindication participate ( like cardiac defect serious central nervous system disease ) present . In follow diagnostic session therapist conduct standardized assessment four diagnostic session therapy start . All patient receive six therapy session , whereof three consist exposure . When exposure successful , D-Cycloserine Placebo administer afterwards . At last therapy session another clinical examination control several parameter conduct . One month therapy , two follow-up session assessment take place .</detailed_description>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Agoraphobia</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<criteria>write consent ( per AMG §40 ( 1 ) 3b ) diagnosis agoraphobia ; severity disorder due CGI least `` moderately ill '' age : 1875 year negative pregnancy test premenopausal woman safe contraception ( Pearlindex &lt; 1 ) study accessibility ( geographical vicinity ) treatment followup Compliance patient Known overreaction take DCycloserine Actual pharmacotherapy ethionamides and/ isoniazide Judicial regulatory hospitalization mental institution ( per AMG §40 ( 1 ) 4 ) Severe psychiatric disorder like schizophrenia , addiction dementia acute suicidal tendency epilepsy diseases concern CNS ( e.g . brain tumor , encephalitis ) internal disease like severe hypertension , cardiac insufficiency , cardiac arrhythmia , severe dysfunction liver kidney , insulindependent diabetes mellitus disorder hematopoiesis lactation change psychopharmacotherapy discontinuation pretreatment psychoactive drug le 4 week previous begin study disturbance day night rhythm disorderspecific psychotherapy participation another AMGstudy last month previous inclusion study participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>agoraphobia</keyword>
	<keyword>panic disorder</keyword>
	<keyword>D-Cycloserine</keyword>
	<keyword>DCS</keyword>
	<keyword>exposure</keyword>
	<keyword>cognitive behavioral therapy</keyword>
	<keyword>CBT</keyword>
	<keyword>augmentation</keyword>
</DOC>